Summary of clinical responses at week 16
| Clinical end point | Infliximab(n = 13) | Etanercept(n = 14) |
|---|---|---|
| ACR20, American College of Rheumatology 20% improvement; ACR50, American College of Rheumatology 50% improvement; DAS28, Disease Activity Score based on 28 joints; HAQ, Health Assessment Questionnaire. | ||
| ACR20 | ||
| n (%) | 8 (61.5%) | 4 (28.6%) |
| ACR50 | ||
| n (%) | 4 (30.7%) | 2 (14.3%) |
| DAS28 | ||
| Mean (SD) | 4.0 (1.5) | 5.2 (1.6) |
| % change from baseline | −30.8 (28.6) | −16.0 (24.2) |
| Patients with DAS28 score <2.6 | ||
| n (%) | 2 (15.4%) | 1 (7.1%) |
| Patients with HAQ decrease >0.22 | ||
| n (%) | 8 (61.5%) | 2 (14.3%) |
| Patients with HAQ decrease >0.40 | ||
| n (%) | 5 (38.5%) | 0 (0.0%) |